Quantbot Technologies LP Cuts Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Quantbot Technologies LP reduced its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 66.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,546 shares of the company's stock after selling 25,215 shares during the quarter. Quantbot Technologies LP's holdings in LivaNova were worth $581,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of LIVN. Nordea Investment Management AB grew its stake in LivaNova by 22.2% in the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock worth $3,188,000 after purchasing an additional 12,470 shares during the period. Harbor Capital Advisors Inc. purchased a new position in shares of LivaNova during the fourth quarter valued at approximately $1,954,000. KBC Group NV lifted its holdings in shares of LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after buying an additional 56,580 shares during the period. Rhumbline Advisers lifted its holdings in LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after acquiring an additional 899 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after buying an additional 1,424 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LIVN shares. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Barclays decreased their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research report on Friday, March 7th. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group lowered their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $61.17.

LivaNova Trading Down 0.6 %

NASDAQ:LIVN traded down $0.25 on Tuesday, reaching $39.03. The company's stock had a trading volume of 532,227 shares, compared to its average volume of 610,314. The stock has a 50 day moving average price of $44.12 and a 200 day moving average price of $48.35. LivaNova PLC has a 12-month low of $36.85 and a 12-month high of $64.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 92.93 and a beta of 1.10.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.